| |
| |
|
| Insider
Information: |
Khattar Jack A. |
| Relationship: |
Director |
| City: |
Rockville |
| State: |
MD |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
1,370,341 |
|
|
Indirect Shares
|
2,118,700 |
|
|
| Direct
Value |
$24,033,598 |
|
|
|
Indirect Value
|
$26,849,537 |
|
|
| Total
Shares |
3,489,041 |
|
|
| Total
Value |
$50,883,135 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -42.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Supernus Pharmaceuticals Inc |
SUPN |
President, CEO, Director |
2024-02-28 |
915,217 |
2024-02-28 |
1,022,450 |
Premium* |
|
|
Tesaro, Inc. |
TSRO |
President, CEO, Director |
2016-03-29 |
444,124 |
2016-03-29 |
1,096,250 |
Premium* |
|
|
Scpharmaceuticals Inc. |
SCPH |
Director |
2021-12-03 |
5,000 |
2021-12-03 |
0 |
Premium* |
|
|
Cognition Therapeutics Inc |
CGTX |
Director |
2023-06-09 |
6,000 |
2023-06-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
98 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SUPN |
Supernus Pharmaceuticals ... |
President, CEOOfficer |
• • – |
2012-04-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
397,058 |
|
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEOOfficer |
• • – |
2012-04-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,125,000 |
|
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-03 |
4 |
S |
$42.02 |
$8,404 |
D/D |
(200) |
804,272 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2017-12-22 |
4 |
GA |
$0.00 |
$0 |
I/I |
250 |
2,500 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-01 |
4 |
AS |
$42.01 |
$12,602 |
D/D |
(300) |
795,159 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-03 |
4 |
OE |
$9.56 |
$3,155 |
D/D |
330 |
804,472 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2019-01-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
400 |
2,900 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-01 |
4 |
OE |
$9.56 |
$4,761 |
D/D |
498 |
795,459 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2022-11-21 |
4 |
AS |
$35.01 |
$18,592 |
D/D |
(531) |
781,059 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2022-11-22 |
4 |
AS |
$35.00 |
$21,001 |
D/D |
(600) |
781,418 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2017-12-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
750 |
449,654 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2022-11-21 |
4 |
OE |
$9.56 |
$8,107 |
D/D |
848 |
781,590 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2022-11-22 |
4 |
OE |
$9.56 |
$9,168 |
D/D |
959 |
782,018 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-01-31 |
4 |
AS |
$42.01 |
$41,002 |
D/D |
(976) |
794,961 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2015-12-28 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,000 |
2,250 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2019-12-26 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,100 |
4,000 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2022-11-15 |
4 |
AS |
$35.00 |
$39,028 |
D/D |
(1,115) |
780,742 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2019-01-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,200 |
453,065 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2014-08-25 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,250 |
1,250 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2022-09-14 |
4 |
OE |
$33.75 |
$46,575 |
D/D |
1,380 |
780,074 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-01-31 |
4 |
OE |
$9.56 |
$15,487 |
D/D |
1,620 |
795,937 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2022-11-15 |
4 |
OE |
$9.56 |
$17,045 |
D/D |
1,783 |
781,857 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2022-11-23 |
4 |
AS |
$35.05 |
$79,189 |
D/D |
(2,259) |
782,775 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2015-12-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
436,434 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2019-12-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,300 |
461,841 |
0 |
- |
|
98 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
